UAB Medicine recently established a colorectal oncology clinic to provide a hassle-free experience for diagnosis and treatment.
Clinical trials from the final Department of Medicine divisions recently went live in OnCore, marking the successful completion of another major phase of the implementation plan. OnCore is replacing the older, and no longer supported, SiteMinder system.
The UAB Comprehensive Cancer Center has received a prominent national Innovator Award from the Association of Community Cancer Centers (ACCC) for its Patient Care Connect Program. The award is given only to ACCC members that are forward-thinking in creating replicable solutions to improve access, quality and value of patient care.
A UAB researcher has received a 2017 Susan G. Komen grant to investigate combination drug therapies for HER2-positive breast cancer.
Recent findings from an innovative nationwide trial indicate that the drug pembrolizumab, when used in combination with standard therapy, may provide positive results for patients with locally advanced breast cancer.
Michael Birrer, a leading medical oncologist at Harvard University, will take the reins as the new director of the UAB Comprehensive Cancer Center, succeeding the retiring Edward Partridge.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
A UAB study shows specialized treatment sites contribute to better survival rates for those with acute leukemia.
Research from UAB suggests that nearly half of children with the most common type of leukemia or their parents say they took more medications than they actually did.
UAB’s innovative Patient Care Connect Program utilizes lay navigation and provides a cost-effective new model for cancer care delivery.